Hema Now
In this episode of Hema Now, Marilyn Manco-Johnson explores the evolution and future of paediatric haemophilia care. From the early adoption of prophylactic treatment to today’s rapidly advancing therapeutic landscape, she reflects on the milestones that have transformed outcomes for children. The conversation also dives into ongoing challenges, including joint health, variability in treatment response, and access to care, while highlighting emerging innovations such as gene therapy and non-factor therapies that could redefine long-term management.
Spotify | Apple | Amazon Music | YouTube | Download MP3 (24 mins)
Marilyn Manco-Johnson is a leading expert in paediatric haematology, internationally recognised for her contributions to haemophilia research and care. Based at the University of Colorado School of Medicine and the Mountain States Regional Hemophilia and Thrombosis Center, Aurora, Colorado, USA, her research has played a pivotal role in transforming the management of haemophilia in children. She continues to lead research focused on optimising therapies and addressing unmet needs in paediatric haemophilia.
Timestamps:
00:00 – Introduction
00:49 – Career inspiration
04:40 – Prophylaxis turning points
09:41 – Key care advances
12:12 – Current research questions
15:00 – Joint risk factors
19:10 – Emerging therapies impact
24:24 – Recognising joint pain
26:08 – Gaps in care
29:11 – Future priorities
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
